Rebound growth of infantile hemangiomas after propranolol therapy

Sonal D. Shah, Eulalia Baselga, Catherine McCuaig, Elena Pope, Julien Coulie, Laurence M. Boon, Maria C. Garzon, Anita Haggstrom, Denise Adams, Beth A. Drolet, Brandon D. Newell, Julie Powell, Maria Teresa García-Romero, Carol Chute, Esther Roe, Dawn H. Siegel, Barbara Grimes, Ilona J. Frieden

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background and Objectives: Propranolol is first-line therapy for problematic infantile hemangiomas (IHs). Rebound growth after propranolol discontinuation is noted in 19% to 25% of patients. Predictive factors for rebound are not completely understood and may alter the management approach. The goal of the study was to describe a cohort of patients with IHs treated with propranolol and to identify predictors for rebound growth. Methods: A multicenter retrospective cohort study was conducted in patients with IHs treated with propranolol. Patient demographic characteristics, IH characteristics, and specifics of propranolol therapy were obtained. Episodes of rebound growth were recorded. Patients' responses to propranolol were evaluated through a visual analog scale. Results: A total of 997 patients were enrolled. The incidence of rebound growth was 231 of 912 patients (25.3%). Mean age at initial rebound was 17.1 months. The odds of rebound among those who discontinued therapy at

Original languageEnglish (US)
JournalPediatrics
Volume137
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Hemangioma
Propranolol
Growth
Therapeutics
Visual Analog Scale
Cohort Studies
Retrospective Studies
Demography
Incidence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Shah, S. D., Baselga, E., McCuaig, C., Pope, E., Coulie, J., Boon, L. M., ... Frieden, I. J. (2016). Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics, 137(4). https://doi.org/10.1542/peds.2015-1754

Rebound growth of infantile hemangiomas after propranolol therapy. / Shah, Sonal D.; Baselga, Eulalia; McCuaig, Catherine; Pope, Elena; Coulie, Julien; Boon, Laurence M.; Garzon, Maria C.; Haggstrom, Anita; Adams, Denise; Drolet, Beth A.; Newell, Brandon D.; Powell, Julie; García-Romero, Maria Teresa; Chute, Carol; Roe, Esther; Siegel, Dawn H.; Grimes, Barbara; Frieden, Ilona J.

In: Pediatrics, Vol. 137, No. 4, 01.04.2016.

Research output: Contribution to journalArticle

Shah, SD, Baselga, E, McCuaig, C, Pope, E, Coulie, J, Boon, LM, Garzon, MC, Haggstrom, A, Adams, D, Drolet, BA, Newell, BD, Powell, J, García-Romero, MT, Chute, C, Roe, E, Siegel, DH, Grimes, B & Frieden, IJ 2016, 'Rebound growth of infantile hemangiomas after propranolol therapy', Pediatrics, vol. 137, no. 4. https://doi.org/10.1542/peds.2015-1754
Shah SD, Baselga E, McCuaig C, Pope E, Coulie J, Boon LM et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016 Apr 1;137(4). https://doi.org/10.1542/peds.2015-1754
Shah, Sonal D. ; Baselga, Eulalia ; McCuaig, Catherine ; Pope, Elena ; Coulie, Julien ; Boon, Laurence M. ; Garzon, Maria C. ; Haggstrom, Anita ; Adams, Denise ; Drolet, Beth A. ; Newell, Brandon D. ; Powell, Julie ; García-Romero, Maria Teresa ; Chute, Carol ; Roe, Esther ; Siegel, Dawn H. ; Grimes, Barbara ; Frieden, Ilona J. / Rebound growth of infantile hemangiomas after propranolol therapy. In: Pediatrics. 2016 ; Vol. 137, No. 4.
@article{1fc7f80f1537454c97d5a127bb596459,
title = "Rebound growth of infantile hemangiomas after propranolol therapy",
abstract = "Background and Objectives: Propranolol is first-line therapy for problematic infantile hemangiomas (IHs). Rebound growth after propranolol discontinuation is noted in 19{\%} to 25{\%} of patients. Predictive factors for rebound are not completely understood and may alter the management approach. The goal of the study was to describe a cohort of patients with IHs treated with propranolol and to identify predictors for rebound growth. Methods: A multicenter retrospective cohort study was conducted in patients with IHs treated with propranolol. Patient demographic characteristics, IH characteristics, and specifics of propranolol therapy were obtained. Episodes of rebound growth were recorded. Patients' responses to propranolol were evaluated through a visual analog scale. Results: A total of 997 patients were enrolled. The incidence of rebound growth was 231 of 912 patients (25.3{\%}). Mean age at initial rebound was 17.1 months. The odds of rebound among those who discontinued therapy at",
author = "Shah, {Sonal D.} and Eulalia Baselga and Catherine McCuaig and Elena Pope and Julien Coulie and Boon, {Laurence M.} and Garzon, {Maria C.} and Anita Haggstrom and Denise Adams and Drolet, {Beth A.} and Newell, {Brandon D.} and Julie Powell and Garc{\'i}a-Romero, {Maria Teresa} and Carol Chute and Esther Roe and Siegel, {Dawn H.} and Barbara Grimes and Frieden, {Ilona J.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1542/peds.2015-1754",
language = "English (US)",
volume = "137",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

TY - JOUR

T1 - Rebound growth of infantile hemangiomas after propranolol therapy

AU - Shah, Sonal D.

AU - Baselga, Eulalia

AU - McCuaig, Catherine

AU - Pope, Elena

AU - Coulie, Julien

AU - Boon, Laurence M.

AU - Garzon, Maria C.

AU - Haggstrom, Anita

AU - Adams, Denise

AU - Drolet, Beth A.

AU - Newell, Brandon D.

AU - Powell, Julie

AU - García-Romero, Maria Teresa

AU - Chute, Carol

AU - Roe, Esther

AU - Siegel, Dawn H.

AU - Grimes, Barbara

AU - Frieden, Ilona J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background and Objectives: Propranolol is first-line therapy for problematic infantile hemangiomas (IHs). Rebound growth after propranolol discontinuation is noted in 19% to 25% of patients. Predictive factors for rebound are not completely understood and may alter the management approach. The goal of the study was to describe a cohort of patients with IHs treated with propranolol and to identify predictors for rebound growth. Methods: A multicenter retrospective cohort study was conducted in patients with IHs treated with propranolol. Patient demographic characteristics, IH characteristics, and specifics of propranolol therapy were obtained. Episodes of rebound growth were recorded. Patients' responses to propranolol were evaluated through a visual analog scale. Results: A total of 997 patients were enrolled. The incidence of rebound growth was 231 of 912 patients (25.3%). Mean age at initial rebound was 17.1 months. The odds of rebound among those who discontinued therapy at

AB - Background and Objectives: Propranolol is first-line therapy for problematic infantile hemangiomas (IHs). Rebound growth after propranolol discontinuation is noted in 19% to 25% of patients. Predictive factors for rebound are not completely understood and may alter the management approach. The goal of the study was to describe a cohort of patients with IHs treated with propranolol and to identify predictors for rebound growth. Methods: A multicenter retrospective cohort study was conducted in patients with IHs treated with propranolol. Patient demographic characteristics, IH characteristics, and specifics of propranolol therapy were obtained. Episodes of rebound growth were recorded. Patients' responses to propranolol were evaluated through a visual analog scale. Results: A total of 997 patients were enrolled. The incidence of rebound growth was 231 of 912 patients (25.3%). Mean age at initial rebound was 17.1 months. The odds of rebound among those who discontinued therapy at

UR - http://www.scopus.com/inward/record.url?scp=84962623962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962623962&partnerID=8YFLogxK

U2 - 10.1542/peds.2015-1754

DO - 10.1542/peds.2015-1754

M3 - Article

C2 - 26952504

AN - SCOPUS:84962623962

VL - 137

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

ER -